Igene Biotechnology Long Term Debt

The latest long-term debt for IGNE is $5.7M as of September 2010. That compares with $5.7M in the prior-year period — up 0.7% year over year. Investors often review this figure alongside Igene Biotechnology's historical trend and sector peers before judging valuation or financial health.

Over the past year, IGNE's long-term debt moved from $5.7M to $5.7M — a 0.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Igene Biotechnology's operating scale or balance-sheet position.

A long-term debt figure of $5.7M for IGNE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting IGNE's long-term debt ($5.7M), review year-over-year change from $5.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.